contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


medivir-presenting-at-the-redeye-life-science-day-2025

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Medivir utvecklar läkemedel med fokus på cancersjukdomar där de medicinska behoven är stora. Läkemedelskandidaterna riktas mot indikationsområden där tillgängliga behandlingsmetoder är begränsade eller saknas. Medivir fokuserar på utvecklingen av fostrox, en läkemedelskandidat som har utformats för att selektivt behandla cancerceller i levern. Bolaget grundades 1988 och har huvudkontor i Huddinge.

Medivir

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the...

<div class="mfn-preamble"><p><strong>Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Redeye Life Science Day 2025, December 3, at 08.50 CET.</strong></p></div><div class="mfn-body"><p>CEO Jens Lindberg will present the upcoming randomized, controlled two-arm study with 40 patients in each arm. The objective of the study is to show that the Company’s drug candidate fostrox in combination with lenvatinib is superior to lenvatinib alone in second-line liver cancer.<br><strong>&nbsp;</strong><br>The presentation is live broadcasted and can be followed via the link; <a rel="noopener" href="https://www.redeye.se/events/1111918/redeye-life-science-day-2025?tab=attendingcompanies">HERE</a>.<br>&nbsp;<br>The presentation will be available after the meeting on Medivirs website; <a rel="noopener" href="http://www.medivir.com">www.medivir.com</a>.&nbsp;</p></div><div class="mfn-footer mfn-contacts mfn-9771c060c61c"><p><strong class="mfn-heading-1">For additional information, please contact;</strong><br>Magnus Christensen<br>Chief Financial Officer<br>Medivir AB<br>Telephone: +46 8 5468 3100<br>Email: <a rel="noopener" href="mailto:Magnus.Christensen@medivir.com">Magnus.Christensen@medivir.com</a></p></div><div class="mfn-footer mfn-about mfn-1cf93d4e26af"><p><strong class="mfn-heading-1">About Medivir</strong><br>Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a drug candidate designed to selectively treat cancer cells in the liver and to minimize side effects. Collaborations and partnerships are important parts of Medivir’s business model, and the drug development is conducted either by Medivir or in partnership. Medivir’s share (ticker: MVIR) is listed on Nasdaq Stockholm’s Small Cap list. <a rel="noopener" href="http://www.medivir.com">www.medivir.com</a>.&nbsp;</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/58c9e30d-26d6-476e-9fee-ff582e8a187d/press-release-pdf.pdf" class="mfn-generated mfn-primary">Press Release (PDF)</a></p></div>

Medivir presenting at the Redeye Life Science Day 2025

USA:s Black Week ledde till överraskande inköp

Uppgångsvecka bakom oss, Tyskland gick vidare med sin megabudget

Måste man arbeta långa dagar? Ekonomen funderar

Finlands ekonomiska tillväxt: ”Varje dag och varje natt tänker jag på dig”

Nedgångsvecka bakom oss, AI-oron når även obligationsmarknaden